Bristol Myers Squibb and Janssen Pharmaceuticals Collaborate to Receive FDA Fast Track Designation for Milvexian

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor, have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexiadevelopment programme (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia programme is unrivalled as the most comprehensive FXIa clinical development programme to date and will provide extensive data from nearly 50,000 patients. Despite major advances in cardiovascular and stroke treatment over the past two decades, millions of patients currently remain untreated or undertreated due to the risk of bleeding. If successful, milvexian will open the door to treat an entirely new set of patients, currently overlooked due to bleeding risk. Milvexian is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) being studied for the prevention and treatment of major thrombotic conditions as part of the Librexia programme, the most comprehensive FXIa clinical development programme to date. Milvexian is an investigational agent and has not been approved for use in any country, for any indication.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!